prikaz prve stranice dokumenta ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination
  Download
PDF 904.43 KB
Scientific paper - Preliminary note / Short communication
ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination
European Journal of Immunology, 52 (2022), 6; 936-945. https://doi.org/10.1002/eji.202249823
Cokarić Brdovčak, Maja; Materljan, Jelena; Šustić, Marko; Ravlić, Sanda; Ružić, Tina; Lisnić, Berislav; Miklić, Karmela; Brizić, Ilija; Pribanić Matešić, Marina; Juranić Lisnić, Vanda; Halassy, Beata; Rončević, Dobrica; Knežević, Zdravka; Štefan, Leo; Bertoglio, Federico; Schubert, Maren; Čičin‐Šain, Luka; Markotić, Alemka; Jonjić, Stipan; Krmpotić, Astrid More authors...

Linked objects
COVID-19 (zbirka 2.) | Virtual collection
Cite this document

Cokarić Brdovčak, M., Materljan, J., Šustić, M., Ravlić, S., Ružić, T., Lisnić, B. ... Krmpotić, A. (2022). ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. European Journal of Immunology, 52. (6), 936-945. doi: 10.1002/eji.202249823

Cokarić Brdovčak, Maja, et al. "ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination." European Journal of Immunology, vol. 52, no. 6, 2022, pp. 936-945. https://doi.org/10.1002/eji.202249823

Cokarić Brdovčak, Maja, Jelena Materljan, Marko Šustić, Sanda Ravlić, Tina Ružić, Berislav Lisnić, Karmela Miklić, et al. "ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination." European Journal of Immunology 52, no. 6 (2022): 936-945. https://doi.org/10.1002/eji.202249823

Cokarić Brdovčak, M., et al. (2022) 'ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination', European Journal of Immunology, 52(6), pp. 936-945. doi: 10.1002/eji.202249823

Cokarić Brdovčak M, Materljan J, Šustić M, Ravlić S, Ružić T, Lisnić B, and sur.. ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. European Journal of Immunology [Internet]. 2022 March 31 [cited 2024 November 16];52(6):936-945. doi: 10.1002/eji.202249823

M. Cokarić Brdovčak, et al., "ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination", European Journal of Immunology, vol. 52, no. 6, pp. 936-945, March 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:945601. [Accessed: 16 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination
AuthorMaja Cokarić Brdovčak
AuthorJelena Materljan
AuthorMarko Šustić https://orcid.org/0000-0001-8213-0578
AuthorSanda Ravlić
AuthorTina Ružić
AuthorBerislav Lisnić
AuthorKarmela Miklić
AuthorIlija Brizić
AuthorMarina Pribanić Matešić
AuthorVanda Juranić Lisnić
AuthorBeata Halassy
AuthorDobrica Rončević
AuthorZdravka Knežević
AuthorLeo Štefan
AuthorFederico Bertoglio
AuthorMaren Schubert
AuthorLuka Čičin‐Šain
AuthorAlemka Markotić
AuthorStipan Jonjić
AuthorAstrid Krmpotić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Immunology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
COVID‐19 vaccines prevent severe forms of the disease, but do not warrant complete protection against breakthrough infections. This could be due to suboptimal mucosal immunity at the site of virus entry, given that all currently approved vaccines are administered via the intramuscular route. In this study, we assessed humoral and cellular immune responses in BALB/c mice after intranasal and intramuscular immunization with adenoviral vector ChAdOx1‐S expressing full‐length Spike protein of SARS‐CoV‐2. We showed that both routes of vaccination induced a potent IgG antibody response, as well as robust neutralizing capacity, but intranasal vaccination elicited a superior IgA antibody titer in the sera and in the respiratory mucosa. Bronchoalveolar lavage from intranasally immunized mice efficiently neutralized SARS‐CoV‐2, which has not been the case in intramuscularly immunized group. Moreover, substantially higher percentages of epitope‐specific CD8 T cells exhibiting a tissue resident phenotype were found in the lungs of intranasally immunized animals. Finally, both intranasal and intramuscular vaccination with ChAdOx1‐S efficiently protected the mice after the challenge with recombinant herpesvirus expressing the Spike protein. Our results demonstrate that intranasal application of adenoviral vector ChAdOx1‐S induces superior mucosal immunity and therefore could be a promising strategy for putting the COVID‐19 pandemic under control.
Keywords (english)
Languageenglish
Publication typeScientific paper - Preliminary note / Short communication
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleEuropean Journal of Immunology
Numberingvol. 52, no. 6, pp. 936-945
p-ISSN0014-2980
e-ISSN1521-4141
DOIhttps://doi.org/10.1002/eji.202249823
URN:NBNurn:nbn:hr:184:945601
Publication2022-03-31
ProjectNumber: IP-CORONA-2020-04-2073
Title (croatian): Dosta skrivanja CoV-2: uspostava baze monoklonskih protutijela na SARS-Cov-2
Title (english): No more hiding CoV-2: Establishment of SARS-Cov-2 mAbeom
Acronym: CoV2mAbs
Leader: Ilija Brizić
Jurisdiction: Croatia
Funding stream: IP-CORONA
ProjectNumber: IP-CORONA-2020-04-2053
Title (croatian): Stvaranje preduvjeta za uvođenje SARS-CoV-2 seroterapije u Hrvatskoj
Leader: Beata Halassy
Jurisdiction: Croatia
Funding stream: IP-CORONA
Document URLhttps://onlinelibrary.wiley.com/doi/10.1002/eji.202249823
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-06-23 12:08:36